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Introduction: Primary laryngeal lymphomas are exceedingly rare. Only about a hundred cases have been reported.
They consist mainly of non-Hodgkin lymphoma, especially of diffuse large B-cell lymphoma and mucosa-associated
lymphoid tissue. We report the first case of a primary laryngeal mantle cell lymphoma.
Case presentation: We report a case of a primary mantle cell lymphoma of the larynx in a 70-year-old North
African non-smoker male. We present a detailed report of his clinical and paraclinical data as well as treatment
options.
Conclusions: Mantle cell lymphoma is a very aggressive lymphoma subset associated with poor prognosis.
Laryngeal mantle cell lymphoma is exceedingly rare. To the best of our knowledge, this is the first case to ever be
reported.Introduction
Primary laryngeal lymphoma is extremely rare, account-
ing for less than 1% of all primary laryngeal neoplasms
[1]. Fewer than 100 cases have been reported in the lit-
erature [1]. They consist mainly of non-Hodgkin lymph-
omas (NHLs) and are predominantly located in the
supraglottic region, as this area of the larynx contains
follicular lymphoid tissue [2]. Among the subtypes of
NHL, diffuse large B-cell and mucosa-associated lymph-
oid tissue lymphomas are the most commonly encoun-
tered primary laryngeal hematopoietic neoplasms [1]. To
the best of our knowledge, no prior case of mantle cell
lymphoma (MCL) of the larynx has been reported; this
subtype represents only 6% of lymphomas, regardless
of the localization [3,4]. We report a case of primary
MCL of the larynx in a 70-year-old male, with a re-
view of the main features of this subset of extranodal
lymphoma.
Case presentation
We report the case of a 70-year-old North African man
who, two months prior to medical examination, presented* Correspondence: nacirisarah05@hotmail.com; dr.a.bennani@gmail.com
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reproduction in any medium, provided the orwith mild laryngeal respiratory distress that worsened
until he ultimately required a tracheotomy. A direct laryn-
goscopy had been performed, revealing a subglottic,
submucosal lump. A biopsy revealed a mantle cell
type B NHL with the following antigen constellation:
cluster of differentiation (CD)5+, CD20+, CD23-, cyclin
D1+. Importantly, a physical examination and computed
tomography (CT) scans showed a lack of lymph node in-
volvement, establishing the larynx as the primary site of
the neoplastic lesion.
The patient’s history and physical examination found
no comorbidities. The patient did not present any B
symptoms and had a performance status 3 as measured
using the World Health Organization performance scale.
During a follow-up four weeks after his initial admission,
a physical examination found laterocervical lymph
nodes. An investigation into possible tumoral extension
by cervical, thoracoabdominal and pelvic CT scans
showed a subglottic tumor (Figures 1 and 2) and cervical
lymph nodes.
A bone marrow biopsy did not show any anomalies. A
blood workup showed he had normal red blood cell
sedimentation rate and lactate dehydrogenase levels.
The patient, who has been staged IIEAa (Ann
Arbor Classification), received one course of rituximab-
cyclophosphamide, doxorubicin, vincristine and prednisonetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Computed tomography scan showing the upper
glottis area free of any tumor.
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opsy was performed in compliance with the family’s
wish.Figure 2 Computed tomography scan showing a subglottic tumor co
subglottic tumor while the glottis area is free of disease (Figure 1).Discussion
Extranodal NHL accounts for 20 to 30% of all lymphomas,
while MCL represents only 6% of all NHL subtypes, both
nodal and extranodal [3,4]. Laryngeal NHL is exceedingly
rare, with very few published cases; to the best of our
knowledge, we report the first case of a laryngeal MCL.
Most lymphomas involving the larynx involve other
sites as well, including the salivary glands, the thyroid,
the nasopharynx and tonsils [1]. The most common site
of primary laryngeal lymphomas is the supraglottic
region, as it contains lymphoid collections in the lamina
propria and in the ventricles [2]. In this case, the tumor
localized in the subglottic region of the larynx and
involved no other sites as assessed by a thorough ear,
nose and throat examination and CT scans.
The age of onset for laryngeal lymphomas varies be-
tween 4 and 81 years, with the mean age of occurrence
being in the seventh decade (the patient was 70 years old);
the distribution between males and females is similar [5].
The symptoms at presentation are common to other
laryngeal neoplasms, i.e. hoarseness, dysphonia, dyspha-
gia, stridor, cough and other systemic symptoms, such as
weight loss and fever [5]. In some cases, the disease is
revealed by a threatening dyspnea requiring an urgent
tracheotomy as it was the case with this patient. The
mechanical airway obstruction explains the obvious
similarity with laryngeal squamous cell carcinoma.
Primary laryngeal lymphomas constitute a diagnostic
challenge because they are characterized by the absence of
clinical and gross differential criteria, as compared to
squamous cell carcinoma.mpletely obstructing the laryngeal lumen. Arrow shows the
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lished from 1996 to 2008 shows that 47% were located
in the supraglottic region, 25% in the glottic area, and
the remainder were either subglottic or transglottic [6].
Regarding the macroscopic characteristics of the
reported cases, 20 of 36 cases (55%) were described ei-
ther as smooth or submucosal masses, whereas only two
cases (5.5%) were ulcerated lesions [6]. While imaging
techniques such as CT and magnetic resonance imaging
may be helpful in the assessment of any laryngeal neo-
plasm [7], a definitive diagnosis requires histological
examination of a biopsy specimen.
A wide spectrum of histological subtypes of laryngeal
lymphomas has been reported. The great majority of la-
ryngeal NHLs are of B-cell lineage, frequently presenting
as diffuse large cell lymphoma; very few are of T-cell
lineage [8,9]. The malignant cell type of classic MCL is
composed of small- to medium-sized lymphocytes with
irregular nuclei and condensed chromatin, though a
broad spectrum of morphologic features ranging from
small cell to blastoid types also exists, and these may re-
flect distinct biologic characteristics. The immunopheno-
type of MCL corresponds to mature, naive pre-germinal
center B-cells that express the antigens CD19, CD20,
CD22, CD79A, immunoglobulin M and/or immunoglobu-
lin D. They usually are CD5+ and CD43+ but CD10- and
CD23-. Cyclin D1 overexpression allows, if there were still
any doubt, to confirm the diagnosis [10,11]. Immunohis-
tochemistry on the patient’s biopsy specimen revealed that
it was CD5+, CD20+, CD23- and cyclin D1+.
While there is not a consensus regarding the treat-
ment of MCL, localized stage I and II patients are usu-
ally treated with chemotherapy and radiotherapy, while
those with disseminated forms (stages III and IV) are
treated with chemotherapy only. MCL is an aggressive
lymphoma with the poorest long-term survival of any
subtype. This might be linked to the fact that they usu-
ally are discovered at an advanced stage. Remission in-
duction using intensive chemotherapy regimens appears
to increase the time to progression; it does not, however,
improve the overall survival [10,11]. Randomized data
have shown that chemotherapy remission rates can be
improved by the addition of rituximab [12-14]. Rituxi-
mab also appears to improve clinical and molecular
responses in patients when used for post-transplant con-
solidation [15,16]. Randomized data have shown the
benefit of autologous stem cell transplantation after
high-dose therapy for patients in first remission. Com-
pared with chemotherapy alone, there is improved
progression-free survival, although an advantage in the
overall survival has yet to be demonstrated [17]. Both
myeloablative and non-myeloablative allogeneic transplants
have been evaluated as another promising treatment op-
tion, which will need further corroboration in largercohorts. Some newer targeted therapies (for example,
bortezomib, thalidomide, temsirolimus, flavopiridol)
that have shown activity are also being evaluated in
larger multicenter trials [18-21].
Conclusion
Laryngeal MCL is exceedingly rare. After an extensive
literature search and to the best of our knowledge, this
is the first reported case. MCL is very aggressive and has
a poor prognosis. There currently is no consensus for a
standardized treatment for this type of lymphoma. New
therapeutic protocols, however, are under evaluation and
may improve the outcome for patients.
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